Skip To Main Content
Alexandra Shimmings on Muck Rack

Alexandra Shimmings

Verified
London
As seen in: In Vivo, Scrip, The Pink Sheet, BioXconomy, Generics Bulletin, HBW Insight, Citeline, Medtech Insight, BioProcess International Magazine
While most people think it's our brain that controls our actions, it's often our heart that gets the biggest workout
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Alexandra

Contact Alexandra, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Alexandra Shimmings’s Biography

Read Full Bio →

Alex has 19 years' experience in writing about the pharmaceutical industry, specialising in drug development, clinical trials and data.

Articles

Spending More To Produce Less? How Industry Productivity Is Really Faring

|
By Alexandra Shimmings Verified
| Scrip Verified
The development journey does not end with approval, so why would the metrics? Norstella’s new Pipeline-to-Patient Productivity Index promises to give the most comprehensive assessment of pharma productivity yet – its inaugural findings capture the many moving parts in getting novel drugs to patients and the scale of the challenges facing the industry. (Shutterstock) How best to quantify pharma R&D productivity and return on investment is a question that has long vexed the industry.
Open in Who Shared Issue with article?

Vykat Safety Concerns Take Shine Off Neurocrine Soleno Buy

|
By Alexandra Shimmings Verified
| Scrip Verified
Seven deaths and other adverse events associated with use of the Prader Willi syndrome drug have led to calls for more caution over its use, but a rival’s Phase III failure has left it more in command the market. • Source: Shutterstock Sales of Neurocrine Biosciences’ Vykat XR are expected to come under pressure following reports of deaths and other serious adverse events associated with the Prader-Willi syndrome (PWS) treatment that came with its recent $2.9bn acquisition of Soleno Therapeutics.
Open in Who Shared Issue with article?

Scrip’s Guide To August 2026: Key Drug Approvals And ESC Data

|
By Alexandra Shimmings Verified
| Scrip Verified
August brings a busy approvals calendar, more big pharma earnings and the ESC cardiology congress. Decisions on an mRNA flu vaccine, narcolepsy, myeloma and FOP products are among those that matter most. A quieter conference schedule is offset by the expectation of brisk product approval activity in August, with a pipeline of first-in-class filings up for decisions by the US Food and Drug Administration.
Open in Who Shared Issue with article?
See all 548 articles